Improving Treatment Together: a protocol for a multi-phase, community-based participatory, and co-design project to improve youth opioid treatment service experiences in British Columbia.

Adolescents Co-design Community-based participatory research Human-centred design Implementation science Opioid use Opioid use disorder Young adults Youth

Journal

Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917

Informations de publication

Date de publication:
14 08 2021
Historique:
received: 26 03 2021
accepted: 06 08 2021
entrez: 15 8 2021
pubmed: 16 8 2021
medline: 26 10 2021
Statut: epublish

Résumé

Opioid use is one of the most critical public health issues as highly potent opioids contribute to rising rates of accidental opioid-related toxicity deaths. This crisis has affected people from all age groups, including youth (ages 15-24) who are in a critical developmental period where the stakes of opioid use are especially high. Efforts to reduce the significant harms of opioid use have focused on the expansion of evidence-based treatments, including medications for opioid use disorder (e.g. buprenorphine). While these treatments are unequivocally life saving, recent evidence suggests that they may not align with youths' needs. Accordingly, the 'Improving Treatment Together' (ITT) project has been designed with the aim to improve youths' opioid treatment service experiences and outcomes by co-developing, implementing, and measuring youth-centred opioid use treatment service innovations. This manuscript describes the protocol for this multi-phase project. The ITT project follows community-based participatory research (CBPR) and strategically integrates co-design processes throughout its four phases. Upon establishing a project partnership between national, provincial and community-based organizations, Phase 1 follows four core elements of human-centred co-design (empathy, needs identification, ideation, prototyping) in nine separate workshops. These workshops will be held in four diverse communities with youth, caregivers and service providers who have accessed or delivered opioid treatment services. Phase 1 will culminate in the co-production of opioid treatment service innovations to be considered by the project's partners for further co-development, pilot testing, and wider implementation during the remaining phases of the project. Throughout each phase, the project will collect and analyse both qualitative and quantitative research and evaluation data to determine the project's impact. This protocol provides a detailed description of the ITT project, with an emphasis on the project's application of co-design and CBPR processes, the planned research and implementation procedures, and the establishment of a unique partnership. To our knowledge, this is one of the first projects to integrate these participatory processes to the design, implementation and measurement of youth-centred opioid treatment services. Embedding these processes throughout each phase of the project will strengthen the relevance and feasibility of the project's service delivery innovations.

Sections du résumé

BACKGROUND
Opioid use is one of the most critical public health issues as highly potent opioids contribute to rising rates of accidental opioid-related toxicity deaths. This crisis has affected people from all age groups, including youth (ages 15-24) who are in a critical developmental period where the stakes of opioid use are especially high. Efforts to reduce the significant harms of opioid use have focused on the expansion of evidence-based treatments, including medications for opioid use disorder (e.g. buprenorphine). While these treatments are unequivocally life saving, recent evidence suggests that they may not align with youths' needs. Accordingly, the 'Improving Treatment Together' (ITT) project has been designed with the aim to improve youths' opioid treatment service experiences and outcomes by co-developing, implementing, and measuring youth-centred opioid use treatment service innovations. This manuscript describes the protocol for this multi-phase project.
METHODS
The ITT project follows community-based participatory research (CBPR) and strategically integrates co-design processes throughout its four phases. Upon establishing a project partnership between national, provincial and community-based organizations, Phase 1 follows four core elements of human-centred co-design (empathy, needs identification, ideation, prototyping) in nine separate workshops. These workshops will be held in four diverse communities with youth, caregivers and service providers who have accessed or delivered opioid treatment services. Phase 1 will culminate in the co-production of opioid treatment service innovations to be considered by the project's partners for further co-development, pilot testing, and wider implementation during the remaining phases of the project. Throughout each phase, the project will collect and analyse both qualitative and quantitative research and evaluation data to determine the project's impact.
DISCUSSION
This protocol provides a detailed description of the ITT project, with an emphasis on the project's application of co-design and CBPR processes, the planned research and implementation procedures, and the establishment of a unique partnership. To our knowledge, this is one of the first projects to integrate these participatory processes to the design, implementation and measurement of youth-centred opioid treatment services. Embedding these processes throughout each phase of the project will strengthen the relevance and feasibility of the project's service delivery innovations.

Identifiants

pubmed: 34391483
doi: 10.1186/s13722-021-00261-7
pii: 10.1186/s13722-021-00261-7
pmc: PMC8364413
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Informations de copyright

© 2021. The Author(s).

Références

CMAJ. 2006 May 23;174(11):1589-94
pubmed: 16717269
Addiction. 2021 Apr;116(4):865-873
pubmed: 32770757
Psychol Addict Behav. 2011 Jun;25(2):194-205
pubmed: 21443291
J Pediatr. 2015 Sep;167(3):605-12.e1-2
pubmed: 26054942
Addiction. 2007 Dec;102(12):1920-30
pubmed: 17916222
J Adolesc Health. 2021 Mar;68(3):632-636
pubmed: 33485735
Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):224-233
pubmed: 29911818
JAMA Pediatr. 2017 Aug 1;171(8):747-755
pubmed: 28628701
Transl Psychiatry. 2020 May 28;10(1):167
pubmed: 32522999
Lancet Public Health. 2019 Feb;4(2):e81-e82
pubmed: 30579840
J Holist Nurs. 2012 Mar;30(1):6-15
pubmed: 21772048
Glob Health Promot. 2021 Mar;28(1):51-59
pubmed: 33601961
Semin Perinatol. 2019 Apr;43(3):123-131
pubmed: 30711195
Int J Drug Policy. 2019 Sep;71:183-188
pubmed: 30718120
Qual Saf Health Care. 2006 Oct;15(5):307-10
pubmed: 17074863
Subst Abuse Treat Prev Policy. 2020 Jan 20;15(1):7
pubmed: 31959189
Health Expect. 2018 Apr;21(2):429-440
pubmed: 29151269
J Adolesc Health. 2018 Nov;63(5):594-600
pubmed: 30348282
Milbank Q. 2016 Jun;94(2):392-429
pubmed: 27265562
Harm Reduct J. 2017 Jul 31;14(1):53
pubmed: 28760146
Am J Bioeth. 2015;15(11):28-30
pubmed: 26575810
JAMA Netw Open. 2018 Dec 7;1(8):e186558
pubmed: 30646334
Addict Sci Clin Pract. 2018 May 7;13(1):15
pubmed: 29730987
SSM Popul Health. 2020 Jun 04;11:100609
pubmed: 32613075
Health Promot Pract. 2020 Jan;21(1):37-48
pubmed: 31131633
Addict Behav. 2018 Nov;86:118-123
pubmed: 29747875
Subst Abuse Treat Prev Policy. 2019 Jun 25;14(1):28
pubmed: 31238952
Health Expect. 2018 Dec;21(6):944-949
pubmed: 29858526
Epidemiol Rev. 2020 Jan 31;42(1):41-56
pubmed: 32239206
Pediatrics. 2016 Sep;138(3):
pubmed: 27550978
Early Interv Psychiatry. 2021 Apr 29;:
pubmed: 33913589
Subst Abuse Treat Prev Policy. 2019 Sep 11;14(1):37
pubmed: 31511016
Health Promot Pract. 2006 Jul;7(3):312-23
pubmed: 16760238
Harm Reduct J. 2019 Jun 10;16(1):37
pubmed: 31182099
Am J Psychiatry. 2003 Jun;160(6):1041-52
pubmed: 12777258
JAMA. 2020 Feb 11;323(6):568-571
pubmed: 32044936
Health Expect. 2016 Aug;19(4):908-19
pubmed: 26202658
Addict Behav. 2009 Mar;34(3):319-22
pubmed: 19022584
Nat Rev Dis Primers. 2020 Jan 9;6(1):3
pubmed: 31919349
Early Interv Psychiatry. 2021 May 18;:
pubmed: 34008340
Pediatrics. 2019 Feb;143(2):
pubmed: 30602544
J Adolesc Health. 2017 Jun;60(6):747-750
pubmed: 28258807
Addiction. 2017 Mar;112(3):466-467
pubmed: 28168794

Auteurs

Kirsten Marchand (K)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada. kmarchand@foundrybc.ca.
Faculty of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. kmarchand@foundrybc.ca.
Department of Occupational Science and Occupational Therapy, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada. kmarchand@foundrybc.ca.
Providence Health Care, St. Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada. kmarchand@foundrybc.ca.

Corinne Tallon (C)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.

Christina Katan (C)

Canadian Centre on Substance Use and Addiction, 75 Albert St #500, Ottawa, ON, K1P 5E7, Canada.

Jill Fairbank (J)

Canadian Centre on Substance Use and Addiction, 75 Albert St #500, Ottawa, ON, K1P 5E7, Canada.

Oonagh Fogarty (O)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.
Faculty of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.

Katrina Marie Pellatt (KM)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.

Roxanne Turuba (R)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.

Steve Mathias (S)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.
Faculty of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Centre for Health Evaluation Outcome Sciences, 588-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Providence Health Care, St. Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
Providence Health Care Research Institute, Vancouver, BC, V6Z 1Y6, Canada.

Skye Barbic (S)

Foundry, 915-1045 Howe Street, Vancouver, BC, V6Z 2A9, Canada.
Faculty of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Department of Occupational Science and Occupational Therapy, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Centre for Health Evaluation Outcome Sciences, 588-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Providence Health Care, St. Paul's Hospital, Vancouver, BC, V6Z 1Y6, Canada.
Providence Health Care Research Institute, Vancouver, BC, V6Z 1Y6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH